Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro.

Moises Dias da Silva Luiz Felipe Pinto Marcus Vinicius Pinto Renata Gervais Santa Rosa Paula Accioli Gabriela Amorim Mariana Guedes Carlos Perez Gomes Roberto Coury Pedrosa Márcia Waddington Cruz

Published in: Arquivos de neuro-psiquiatria (2024)

The treatment with inotersen was effective and well tolerated for the average of 67 months and up to 76 months. Our results are consistent with those of larger phase-III trials.

Keyphrases

phase iii
open label
clinical trial
healthcare
phase ii
randomized controlled trial
adverse drug